Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Coenzyme I for Hematopoietic Recovery After Cord Blood Transplant
NCT06558253Phase 1Recruiting
- Sponsor
- The First Affiliated Hospital of USTC
- Start
- Nov 2024
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nicotinamide adenine dinucleotide in hematological malignancies, sponsored by The First Affiliated Hospital of USTC. Primary endpoint: Adverse Event (AE). Started Nov 2024; status: recruiting.
02
Drugs
nicotinamide adenine dinucleotide
03
Conditions
hematological malignancies
Beyond the preview
Go deeper on NCT06558253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06558253.